pindolol has been researched along with fenoldopam in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cheng, JT; Hsu, CT; Lai, CW; Lee, TL; Yen, ST | 1 |
1 review(s) available for pindolol and fenoldopam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pindolol and fenoldopam
| Article | Year |
|---|---|
Activation of beta3-adrenoceptors by exogenous dopamine to lower glucose uptake into rat adipocytes.
Topics: Adipocytes; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Benzazepines; Biological Transport; Cyclic AMP; Deoxyglucose; Dopamine; Dopamine Agonists; Dopamine Antagonists; Enzyme Inhibitors; Fenoldopam; Glucose; Immunoglobulins, Intravenous; Male; Pindolol; Prazosin; Propranolol; Quinpirole; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Receptors, Adrenergic, beta-3; Thionucleotides | 1998 |